4d pharma plc's (LON:DDDD) Duncan Peyton talks to Proactive London about their additional positive results of a phase II study of Blautix for the treatment of Irritable Bowel Syndrome.
The firm has provided a more detailed analysis of its Live Biotherapeutic, Blautix, which is both significant and supportive of its continued development as an irritable bowel syndrome treatment.
Peyton also comments on their collaboration with Parkinson's UK to establish a Patient Advisory Board.